Are we ready for what is coming? Full text here: The Endless Frontier? The Recent Upsurge of R&D Productivity in Pharmaceuticals https://t.co/NsccMX1qrZ

— Luca Pani (@luca__pani) June 21, 2019

In 2012, Ivacaftor developed by Vertex became the first drug to treat the cause rather than symptoms of cystic fibrosis. Now the structure of the drug bound to its target, the ion channel CFTR, has finally been cracked by the Chen lab at Rockefeller. https://t.co/uXIR0mkS6A pic.twitter.com/8JD8Oke2Cx

— Ash Jogalekar (@curiouswavefn) June 20, 2019

Congrats to associate editor @shsternberg for this cool paper, which he inexplicably chose to publish in @nature “Transposon-encoded CRISPR–Cas systems direct RNA-guided DNA integration” https://t.co/2Te6mntgQd

— The CRISPR Journal (@CRISPRjournal) June 13, 2019

Therapeutic developments for Duchenne muscular dystrophy

nice box1 explanationhttps://t.co/SmpyZbZNqx pic.twitter.com/iIqlBbqp27

— Bertrand Delsuc (@BertrandBio) June 7, 2019

Trends in clinical success rates and therapeutic focus https://t.co/ORRWXlBC4b - a new analysis published today indicates success rates from phase III to launch have improved since the start of the decade while phase II success rates have remained static pic.twitter.com/Tln4YZybIJ

— Nature Rev Drug Disc (@NatRevDrugDisc) May 8, 2019

A chemical inhibitor of the CRISPR–Cas9 gene-editing tool could allow researchers to switch editing on and off in living cells. #ResearchHighlight https://t.co/wcdwl5nU7J

— nature (@nature) May 6, 2019

Review on a target of many deals on past months: NLRP3

The NLRP3 inflammasome: molecular activation and regulation to therapeuticshttps://t.co/hVzxjCraPa pic.twitter.com/bOdm5VJi2J

— Bertrand Delsuc (@BertrandBio) April 29, 2019

A great review in @NatRevDrugDisc on innate immunity targeting #Immunotherapy https://t.co/ia7OMPWScK pic.twitter.com/e6PAmPV0B3

— soria (@jsoriamd) April 12, 2019

There's so much about #AI's black box algorithms. But what about the unknown mechanism of action for ketamine, a derivative of which was just @US_FDA approved for #depression. Now there's some light on that:https://t.co/wvE3A6qUUY by @anna_beyeler pic.twitter.com/CCHfltyQgL

— Eric Topol (@EricTopol) April 11, 2019

“Authors identify a molecular mechanism that activates the transcription of genes related to an inactivated gene, thereby compensating for the knockout.” □ https://t.co/0thdlGLx8L

— Dr. Zoidberg (@psuvafan007) April 5, 2019

A call to retire statistical significance: when > 800 scientists say enough is enough, "The tool has become the tyrant"https://t.co/FIKB3V5h6d
by @vamrhein @Lester_Domes and a long list
with this week's @Nature editorial https://t.co/H4IUcAwmCM pic.twitter.com/RlarATcTao

— Eric Topol (@EricTopol) March 20, 2019

Very proud of this special issue @CellCellPress #editorial, outlining our vision of human #genetics / #genomics research. Where are we now, where are we headed and what do we have to surmount to get there? Would love your thoughts! https://t.co/LVB9LcnKi9 @cellpressnews pic.twitter.com/BZJVL87yC1

— Stacie Dodgson (@sed9) March 21, 2019

Gorgeous story from @NavitorPharma on the discovery of a drug that mimics a natural and specific activating signal for mTORC1 with a biodistribution that enables interesting therapeutic applications, particularly in CNS. Congrats @GVlasuk @ShomitSengupta https://t.co/mrVj8dxBDh

— Vipin Suri (@VipinSuri4) March 11, 2019

terrific collection of papers this week - Focus On Cancer Therapy @NatureMedicinehttps://t.co/1GjcrJlEah#glioblastoma #melanoma #immunotherapy #oncology #pediatric_cancer #microbiome #epigenetics

— Paul D. Rennert (@PDRennert) March 9, 2019

NO link with autism. Period. #VaccinesSaveLives https://t.co/WdYrfq7TWQ

— Raphaël Rousseau (@RaphaelRousseau) March 6, 2019

From the March issue - turning cold tumours hot https://t.co/NmweGXB9Ct Galon and Bruni discuss how understanding the mechanisms responsible for hot, altered or cold immune tumours could be harnessed to improve cancer #immunotherapy pic.twitter.com/Tol4ckFYWA

— Nature Rev Drug Disc (@NatRevDrugDisc) March 4, 2019